Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and vudalimab in CRC with molecular residual disease
NCT05900648Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of vudalimab in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Planned start May 2023; status: withdrawn.
02
Drugs
vudalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05900648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900648.